
Compassionate Registered Nurse with over 30 years of direct patient care experience, including more than 20 years specializing in Endocrinology. Proven ability to effectively communicate complex disease states, products, and access and reimbursement concepts, particularly with Ascendis Pharma. Strong advocate for team collaboration, consistently striving for optimal patient outcomes in fast-paced environments. Equipped with extensive expertise in medical procedures, patient assessments, and care coordination, alongside a solid background in remote work settings.
1. Safety and efficacy of treatment with Lonapegsomatropin in children with growth hormone deficiency at week 130 in the enliGHten trial.
2. Treatment Experience of Children with Growth Hormone Deficiency in the Phase 3 fliGHt Trial: Switching from Daily Growth Hormone to Once-weekly TransCon hGH
3. Continued Efficacy and Safety with up to 2 Years of Treatment with Lonapegsomatropin (TransCon hGH) in Children with Growth Hormone Deficiency
4. Continued Safety and Efficacy After 2.5 Years of Treatment with Lonapegsomatropin-tcgd (TransCon hGH) in Children with Growth Hormone Deficiency in the enliGHten trial.
Product theater for PENS: Understanding SKYTROFA (lonapegsomatropin-tcgd) Following a Patient Journey to Once-weekly Treatment